These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20471832)

  • 1. Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists.
    Zuev D; Vrudhula VM; Michne JA; Dasgupta B; Pin SS; Huang XS; Wu D; Gao Q; Zhang J; Taber MT; Macor JE; Dubowchik GM
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3669-74. PubMed ID: 20471832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of CRF1R binding affinity of 2-(2,4,6-trichlorophenyl)-4-trifluoromethyl-5-aminomethylthiazoles through rapid and selective parallel synthesis.
    Zuev D; Michne JA; Pin SS; Zhang J; Taber MT; Dubowchik GM
    Bioorg Med Chem Lett; 2005 Jan; 15(2):431-4. PubMed ID: 15603967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists.
    Han X; Pin SS; Burris K; Fung LK; Huang S; Taber MT; Zhang J; Dubowchik GM
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4029-32. PubMed ID: 15982881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.
    Han X; Michne JA; Pin SS; Burris KD; Balanda LA; Fung LK; Fiedler T; Browman KE; Taber MT; Zhang J; Dubowchik GM
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3870-3. PubMed ID: 15990298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor.
    Yamada Y; Mizutani K; Mizusawa Y; Hantani Y; Tanaka M; Tanaka Y; Tomimoto M; Sugawara M; Imai N; Yamada H; Okajima N; Haruta J
    J Med Chem; 2004 Feb; 47(5):1075-8. PubMed ID: 14971886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
    Guo Z; Tellew JE; Gross RS; Dyck B; Grey J; Haddach M; Kiankarimi M; Lanier M; Li BF; Luo Z; McCarthy JR; Moorjani M; Saunders J; Sullivan R; Zhang X; Zamani-Kord S; Grigoriadis DE; Crowe PD; Chen TK; Williams JP
    J Med Chem; 2005 Aug; 48(16):5104-7. PubMed ID: 16078829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An orally active corticotropin releasing factor 1 receptor antagonist from 8-aryl-1,3a,7,8-tetraaza-cyclopenta[a]indenes.
    Han X; Civiello R; Pin SS; Burris K; Balanda LA; Knipe J; Ren S; Fiedler T; Browman KE; Macci R; Taber MT; Zhang J; Dubowchik GM
    Bioorg Med Chem Lett; 2007 Apr; 17(7):2026-30. PubMed ID: 17258456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-phenylphenylglycines as novel corticotropin releasing factor receptor antagonists.
    Molteni V; Penzotti J; Wilson DM; Termin AP; Mao L; Crane CM; Hassman F; Wang T; Wong H; Miller KJ; Grossman S; Grootenhuis PD
    J Med Chem; 2004 May; 47(10):2426-9. PubMed ID: 15115386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
    Saito T; Obitsu T; Minamoto C; Sugiura T; Matsumura N; Ueno S; Kishi A; Katsumata S; Nakai H; Toda M
    Bioorg Med Chem; 2011 Oct; 19(20):5955-66. PubMed ID: 21930387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
    Hartz RA; Ahuja VT; Schmitz WD; Molski TF; Mattson GK; Lodge NJ; Bronson JJ; Macor JE
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1890-4. PubMed ID: 20176478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: a novel series of CRF-1 receptor antagonists.
    Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Chandrasekhar J; Horvath RF; Ge P; Kershaw MT; Krause JE; Kehne J; Hoffman D; Doller D; Hodgetts KJ
    Bioorg Med Chem Lett; 2008 Feb; 18(3):891-6. PubMed ID: 18180159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.
    Lowe RF; Nelson J; Dang TN; Crowe PD; Pahuja A; McCarthy JR; Grigoriadis DE; Conlon P; Saunders J; Chen C; Szabo T; Chen TK; Bozigian H
    J Med Chem; 2005 Mar; 48(5):1540-9. PubMed ID: 15743196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.
    Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C
    Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
    Gilligan PJ; Clarke T; He L; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy JF; Ward K; Zeller K; Wong H; Bai S; Saye J; Grossman S; Zaczek R; Arneric SP; Hartig P; Robertson D; Trainor G
    J Med Chem; 2009 May; 52(9):3084-92. PubMed ID: 19361209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists.
    Chen YL; Braselton J; Forman J; Gallaschun RJ; Mansbach R; Schmidt AW; Seeger TF; Sprouse JS; Tingley FD; Winston E; Schulz DW
    J Med Chem; 2008 Mar; 51(5):1377-84. PubMed ID: 18260619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy.
    Dubowchik GM; Michne JA; Zuev D; Schwartz W; Scola PM; James CA; Ruediger EH; Pin SS; Burris KD; Balanda LA; Gao Q; Wu D; Fung L; Fiedler T; Browman KE; Taber MT; Zhang J
    Bioorg Med Chem Lett; 2003 Nov; 13(22):3997-4000. PubMed ID: 14592493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
    Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE
    J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
    Chen C; Wilcoxen KM; Huang CQ; McCarthy JR; Chen T; Grigoriadis DE
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3669-73. PubMed ID: 15203140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.